Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR309 and Eribulin Combination in Patients With Locally Advanced or Metastatic HER2 Negative and Triple-Negative Breast Cancer

NCT02723877 is registered in ClinicalTrials.gov with PIQUR Therapeutics AG as lead sponsor.

NCT NCT02723877
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02723877 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label, Non Randomized, Multicenter Phase 1/2b Study Investigating Safety and Efficacy of PQR309 and Eribulin Combination in Patients With Locally Advanced or Metastatic HER2 Negative and Triple-Negative Breast Cancer
Lead sponsor
PIQUR Therapeutics AG
Phase
Phase 1/2
Overall status
Completed
Start date
March 28, 2016
Completion date
October 3, 2018
Enrollment
41 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer